Reuters logo
BRIEF-PureTech initiates phase 2b inhibitors study in respiratory tract infections
May 9, 2017 / 6:33 AM / 5 months ago

BRIEF-PureTech initiates phase 2b inhibitors study in respiratory tract infections

May 9 (Reuters) - PureTech Health Plc:

* PureTech initiates phase 2b mtorc1 study in rtis

* Announces initiation of phase 2b mtorc1 inhibitors study in elderly patients at increased risk of respiratory tract infections

* Study builds on efficacy and safety data from previous phase 2 clinical studies, which suggest selective targeting of mtorc1 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below